Filtered By:
Condition: Thrombosis
Drug: Pradaxa
This page shows you your search results in order of relevance. This is page number 15.
Order by Relevance | Date
Total 508 results found since Jan 2013.
Efficacy and safety of direct oral anticoagulants in the treatment of left ventricular thrombus after acute anterior myocardial infarction in patients who underwent percutaneous coronary intervention
CONCLUSIONS: DOACs appears to be a suitable alternative to warfarin for the management of LVT post STEMI, especially in patients who are intolerant to warfarin.PMID:36200193 | DOI:10.2174/1570161120666221003104821
Source: Current Vascular Pharmacology - October 6, 2022 Category: Drugs & Pharmacology Authors: Jing Liang Zhijian Wang Yujie Zhou Hua Shen Meng Chai Xiaoteng Ma Hongya Han Qiaoyu Shao Qiuxuan Li Source Type: research
Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease
ConclusionAmong patients with AF and AKD, DOACs were linked to a lower risk of ischemic events, and apixaban was linked to a lower risk of any ischemia and any bleeding than warfarin.
Source: Journal of Thrombosis and Thrombolysis - July 15, 2023 Category: Hematology Source Type: research
Implications of new anticoagulants in primary practice
Conclusion: Rivaroxaban, apixaban and dabigatran etexilate offer the possibility of simplified prevention and treatment strategies for thromboembolic disorders in the outpatient setting.
Source: International Journal of Clinical Practice - January 11, 2013 Category: Internal Medicine Authors: A. Perez, L. H. Eraso, G. J. Merli Tags: SYSTEMATIC REVIEW Source Type: research
Safety of Continuous Anticoagulation With Dabigatran During Implantation of Cardiac Rhythm Devices
In conclusion, although no thromboembolic or major bleeding events were observed, additional studies are required to define the optimal antithrombotic management in the perioperative period.
Source: The American Journal of Cardiology - January 28, 2013 Category: Cardiology Authors: Christopher P. Rowley, Michael L. Bernard, William W. Brabham, Peter C. Netzler, Darren S. Sidney, Frank Cuoco, J. Lacy Sturdivant, Robert B. Leman, J. Marcus Wharton, Michael R. Gold Tags: Arrhythmias and Conduction Disturbances Source Type: research
Adherence to anticoagulant treatment with dabigatran in a real‐world setting
ConclusionIn our clinical practice adherence to the twice‐daily dabigatran regimen was generally good, although 12% of the patients had an inadequate adherence. Routine feedback from the pharmacies could inform the physician to improve the anticoagulant management.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 13, 2013 Category: Hematology Authors: S. Schulman, B. Shortt, M. Robinson, J. W. Eikelboom Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research
Anticoagulation therapy: Long-term dabigatran therapy reduces the risk of recurrent venous thromboembolism
Nature Reviews Cardiology 10, 240 (2013).
doi:10.1038/nrcardio.2013.33
Author: Megan Cully
Effective use of warfarin requires frequent monitoring. Patients treated with dabigatran, a novel oral anticoagulant used to prevent venous thromboembolism (VTE) after joint replacement or to prevent stroke related to atrial fibrillation, do not need to be monitored as often. “Physicians stop anticoagulation after typically
Source: Nature Reviews Cardiology - March 12, 2013 Category: Cardiology Authors: Megan Cully Tags: Research Highlight Source Type: research
A specific antidote for dabigatran: functional and structural characterization
Dabigatran etexilate is a direct thrombin inhibitor and used widely as an anticoagulant for the prevention of stroke in patients with atrial fibrillation. However, anticoagulation therapy can be associated with an increased risk of bleeding. Here, we present data on the identification, humanization, and in vitro pharmacology of an antidote for dabigatran (aDabi-Fab). The X-ray crystal structure of dabigatran in complex with the antidote reveals many structural similarities of dabigatran recognition compared with thrombin. By a tighter network of interactions, the antidote achieves an affinity for dabigatran that is ~350 ti...
Source: Blood - May 2, 2013 Category: Hematology Authors: Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H., Litzenburger, T. Tags: Plenary Papers, Thrombosis and Hemostasis Source Type: research
Managing Blunt Trauma in Patients Receiving Dabigatran Etexilate: Case Study and Review of the Literature
The objectives of this article are to present a case of life-threatening bleeding in a patient receiving dabigatran etexilate, followed by a review of the current literature and a suggested reversal guideline.
Source: Journal of Emergency Nursing: JEN - April 1, 2013 Category: Nursing Authors: Peter Eamonn Croft, Katherine P. Cabral, Tania D. Strout, Michael R. Baumann, Michael A. Gibbs, Matthew C. DeLaney Tags: Trauma Notebook Source Type: research
